By 2040, pancreatic ductal adenocarcinoma (PDAC) is projected to become the second most fatal kind of cancer in humans, and the majority of patients with PDAC will not respond to chemotherapy according to existing treatment protocols. Scientists have identified diet as an environmental element that impacts patients' response to therapy. Nevertheless, its function in the development of pancreatic ductal adenocarcinoma remains unclear.
In a recent study published in the international journal Nature titled "Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer," scientists from the University Medical Center Hamburg and other institutions identified pathways by which gut flora positively influences cancer therapies. In the article, the researchers analyzed the impact of gut microbes on the therapeutic effects of chemotherapy on pancreatic ductal adenocarcinoma.
Previous findings have shown that chemotherapy can sometimes be effective in treating pancreatic cancer that has metastasized, but sometimes it has no effect, and that this difference may be related to the body's resistance to diet, although the source of this is unknown to researchers. In this study, the researchers analyzed the possibility that specific microorganisms in the gut microbiome play a key role, first they analyzed samples from the gut microbiome of pancreatic cancer patients and found some differences between those who responded to the therapy and those who did not, and they also found that mice receiving sterile gut samples from the biome of mice that responded to chemotherapy mice also respond well to chemotherapy.
To better understand the crucial role that the gut microbiome plays in the efficacy of chemotherapy, the researchers collected blood samples from patients who responded to chemotherapy and those who did not, and discovered that the level of a molecule called 3-IAA was also relatively high in patients who responded better. After discovering that this chemical was created by two kinds of gut flora, the researchers attempted to introduce 3-IAA directly. The researchers next tried adding 3-IAA directly to the meal consumed by a mouse cancer model and discovered that the mice were more receptive to treatment. The researchers discovered that 3-IAA is generated in the colon when tryptophan, a molecule present in many meals, is consumed with amino acids, and later examination of cancer mice models suggested that increasing the amount of food containing this molecule might aid chemotherapy treatment.
Researchers investigating why high levels of the chemical 3-IAA improve the efficacy of chemotherapy discovered that the presence of the molecule helps control neutrophils. Overall, bacteria in the gut may be able to combat cancer by sending signals to distant tumors through the blood, where they may increase the production of chemotherapeutic chemicals by enhancing the immune system's ability to operate and so continue to combat the growth of cancer.
In conclusion, the results of this study suggest that researchers have identified a metabolite derived from a microbial community that may have clinical application in the treatment of human pancreatic bile duct adenocarcinoma, which may inspire scientists to consider nutritional intervention strategies in the treatment of cancer patients.
To order this detailed 290+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Key Drug Discovery StepsTarget IdentificationTarget ValidationHit GenerationHit-to-LeadLead Optimization Type of Large MoleculeAntibodiesProteinsPeptidesNucleic AcidsVectors Company SizeSmallMid-sizedLarge Target therapeutic AreaAutoimmune DisordersBlood DisordersCardiovascular DisordersGastrointestinal and Digestive DisordersHormonal DisordersHuman Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)Infectious DiseasesMetabolic DisordersMental DisordersMusculoskeletal DisordersNeurological DisordersOncological DisordersRespiratory DisordersSkin DisordersUrogenital DisordersOthers Type of SponsorIndustry PlayersNon-Industry Players Key Geographical RegionsNorth AmericaEuropeAsia-Pacific The report includes detailed transcripts of discussions held with the following experts:John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)Sven Benson (Founder, candidum)Mark Whittaker (Senior Vice President, Evotec)Edelmiro Moman (Scientific Consultant and Teacher, ProSciens) To request sample pages, please visit this link Key Questions AnsweredWho are the leading in silico service providers for discovery of different types of large molecule drugs?What are the key challenges associated with the discovery of large molecule drugs?What is the likely cost saving opportunity associated with the use of in silico tools?What are the key computational approaches being used by in silico service providers for drug discovery operations?What are the popular business strategies being used by in silico drug discovery service providers?How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:DNA-Encoded Libraries: Platforms and Services MarketGlobal Stem Cells Market: Focus on Clinical Therapies, 2020–2030Companion Diagnostics Services Market, 2020-2030 Contact UsGaurav Chaudhary+1 (415) 800 [email protected]
A product launch is not an easy task by any stretch of the imagination as it involves multiple groups working as a team to churn out the desired results.
Your company might have launched several drugs before but that would not have a huge say in your new venture going smooth.Failures can occur but the key here is to not worry about them and instead learn from them.
We often talk about the success mantras but rarely do we talk about the mistakes that you need to avoid during a product launch.So, here we have listed the three mistakes that you need to definitely avoid while preparing a drug launch.Not thinking about the big pictureOne of the biggest mistakes that you can make is to not think about the big picture right from the beginning.
When it comes to a drug launch, there are innumerable things to keep in mind, like, licensing, target audience, business campaign, marketing strategy, manufacturing speed, product-pitching, and so on.One way to go about the whole process is to focus on just the specific aspects that you feel need the most attention and forget about the rest of the things.
Yes, this can deliver faster results but it can backfire in a huge way in some cases.
Even the smallest of mistakes in neglected areas can jeopardize the whole product launch.Therefore, the right way to go about it is to first identify all the steps involved in the process of product launch and then go through it one-by-one.
